Vontobel Holding Ltd. elevated its holdings in shares of Novavax, Inc. (NASDAQ:NVAX – Free Report) by 110.3% throughout the third quarter, based on the corporate in its most up-to-date disclosure with the Securities and Alternate Fee (SEC). The institutional investor owned 498,532 shares of the biopharmaceutical firm’s inventory after buying a further 261,464 shares throughout the quarter. Vontobel Holding Ltd. owned 0.36% of Novavax price $6,296,000 as of its most up-to-date submitting with the Securities and Alternate Fee (SEC).
Different institutional buyers additionally lately modified their holdings of the corporate. TSP Capital Administration Group LLC boosted its holdings in shares of Novavax by 23.9% throughout the 1st quarter. TSP Capital Administration Group LLC now owns 1,376,950 shares of the biopharmaceutical firm’s inventory valued at $6,582,000 after buying a further 265,250 shares over the past quarter. Swiss Nationwide Financial institution boosted its holdings in Novavax by 17.1% within the first quarter. Swiss Nationwide Financial institution now owns 211,000 shares of the biopharmaceutical firm’s inventory price $1,009,000 after buying a further 30,800 shares over the past quarter. Susquehanna Basic Investments LLC purchased a brand new stake in Novavax within the 1st quarter price roughly $1,499,000. Headlands Applied sciences LLC raised its stake in Novavax by 1,084.0% throughout the 1st quarter. Headlands Applied sciences LLC now owns 55,137 shares of the biopharmaceutical firm’s inventory valued at $264,000 after shopping for a further 50,480 shares over the past quarter. Lastly, ProShare Advisors LLC lifted its holdings in shares of Novavax by 29.9% throughout the 1st quarter. ProShare Advisors LLC now owns 37,203 shares of the biopharmaceutical firm’s inventory valued at $178,000 after shopping for a further 8,570 shares throughout the interval. 53.04% of the inventory is owned by hedge funds and different institutional buyers.
Analysts Set New Value Targets
NVAX has been the topic of plenty of analysis studies. B. Riley reiterated a “purchase” score and set a $26.00 value goal (up beforehand from $23.00) on shares of Novavax in a analysis report on Thursday, October tenth. JPMorgan Chase & Co. upped their value goal on shares of Novavax from $8.00 to $9.00 and gave the corporate an “underweight” score in a analysis report on Monday, August twelfth. Lastly, Jefferies Monetary Group dropped their value goal on shares of Novavax from $31.00 to $25.00 and set a “purchase” score on the inventory in a report on Wednesday. One analyst has rated the inventory with a promote score, three have issued a maintain score and three have assigned a purchase score to the inventory. In keeping with MarketBeat.com, the corporate at present has a median score of “Maintain” and a median value goal of $17.83.
Get Our Newest Inventory Report on NVAX
Novavax Inventory Up 2.0 %
NVAX inventory opened at $10.35 on Friday. The enterprise’s 50-day transferring common value is $12.48 and its 200-day transferring common value is $11.66. The inventory has a market cap of $1.45 billion, a P/E ratio of -3.26 and a beta of two.04. Novavax, Inc. has a twelve month low of $3.53 and a twelve month excessive of $23.86.
Novavax (NASDAQ:NVAX – Get Free Report) final posted its quarterly earnings outcomes on Thursday, August eighth. The biopharmaceutical firm reported $0.99 earnings per share for the quarter, lacking analysts’ consensus estimates of $1.82 by ($0.83). The enterprise had income of $415.50 million for the quarter, in comparison with analyst estimates of $458.57 million. Novavax’s income for the quarter was down 2.1% on a year-over-year foundation. Throughout the identical interval within the prior 12 months, the agency posted $0.58 EPS. On common, equities analysis analysts anticipate that Novavax, Inc. will submit -0.97 earnings per share for the present fiscal 12 months.
Novavax Firm Profile
Novavax, Inc, a biotechnology firm, that promotes improved well being by discovering, growing, and commercializing vaccines to guard towards critical infectious ailments. It affords vaccine platform that mixes a recombinant protein strategy, nanoparticle know-how, and its patented Matrix-M adjuvant to reinforce the immune response.
Featured Tales
Obtain Information & Scores for Novavax Day by day – Enter your e mail deal with beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for Novavax and associated firms with MarketBeat.com’s FREE each day e mail e-newsletter.
